Fibrinolytic potential as a risk factor for postpartum hemorrhage.
ClotPro
PPH
TPA-test
VET
fibrinolytic potential
point-of-care
viscoelastic hemostatic assay
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
04
2023
accepted:
27
07
2023
medline:
25
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
Postpartum hemorrhage (PPH) is still the leading cause of maternal morbidity and mortality worldwide. While impaired fibrin polymerization plays a crucial role in the development and progress of PPH, recent approaches using viscoelastic measurements have failed to sensitively detect early changes in fibrinolysis in PPH. This study aimed to evaluate whether women experiencing PPH show alterations in POC-VET fibrinolytic potential during childbirth and whether fibrinolytic potential offers benefits in the prediction and treatment of PPH. Blood samples were collected at three different timepoints: T0 = hospital admission (19 h ± 18 h prepartum), T1 = 30-60 min after placental separation, and T2 = first day postpartum (19 h ± 6 h postpartum). In addition to standard laboratory tests, whole-blood impedance aggregometry (Multiplate) and viscoelastic testing (VET) were performed using the ClotPro system, which included the TPA-test lysis time, to assess the POC-VET fibrinolytic potential, and selected coagulation factors were measured. The results were correlated with blood loss and clinical outcome markers. Severe PPH was defined as a hemoglobin drop > 4g/dl and/or the occurrence of shock or the need for red blood cell transfusion. Blood samples of 217 parturient women were analyzed between June 2020 and December 2020 at Heidelberg University Women's Hospital, and 206 measurements were eligible for the final analysis. Women experiencing severe PPH showed increased fibrinolytic potential already at the time of hospital admission. When compared to non-PPH, the difference persisted 30-60 min after placental separation. A higher fibrinolytic potential was accompanied by a greater drop in fibrinogen and higher d-dimer values after placental separation. While 70% of women experiencing severe PPH showed fibrinolytic potential, 54% of those without PPH showed increased fibrinolytic potential as well. We were able to show that antepartal and peripartal fibrinolytic potential was elevated in women experiencing severe PPH. However, several women showed high fibrinolytic potential but lacked clinical signs of PPH. The findings indicate that high fibrinolytic potential is a risk factor for the development of coagulopathy, but further conditions are required to cause PPH.
Sections du résumé
Background
UNASSIGNED
Postpartum hemorrhage (PPH) is still the leading cause of maternal morbidity and mortality worldwide. While impaired fibrin polymerization plays a crucial role in the development and progress of PPH, recent approaches using viscoelastic measurements have failed to sensitively detect early changes in fibrinolysis in PPH. This study aimed to evaluate whether women experiencing PPH show alterations in POC-VET fibrinolytic potential during childbirth and whether fibrinolytic potential offers benefits in the prediction and treatment of PPH.
Methods
UNASSIGNED
Blood samples were collected at three different timepoints: T0 = hospital admission (19 h ± 18 h prepartum), T1 = 30-60 min after placental separation, and T2 = first day postpartum (19 h ± 6 h postpartum). In addition to standard laboratory tests, whole-blood impedance aggregometry (Multiplate) and viscoelastic testing (VET) were performed using the ClotPro system, which included the TPA-test lysis time, to assess the POC-VET fibrinolytic potential, and selected coagulation factors were measured. The results were correlated with blood loss and clinical outcome markers. Severe PPH was defined as a hemoglobin drop > 4g/dl and/or the occurrence of shock or the need for red blood cell transfusion.
Results
UNASSIGNED
Blood samples of 217 parturient women were analyzed between June 2020 and December 2020 at Heidelberg University Women's Hospital, and 206 measurements were eligible for the final analysis. Women experiencing severe PPH showed increased fibrinolytic potential already at the time of hospital admission. When compared to non-PPH, the difference persisted 30-60 min after placental separation. A higher fibrinolytic potential was accompanied by a greater drop in fibrinogen and higher d-dimer values after placental separation. While 70% of women experiencing severe PPH showed fibrinolytic potential, 54% of those without PPH showed increased fibrinolytic potential as well.
Conclusion
UNASSIGNED
We were able to show that antepartal and peripartal fibrinolytic potential was elevated in women experiencing severe PPH. However, several women showed high fibrinolytic potential but lacked clinical signs of PPH. The findings indicate that high fibrinolytic potential is a risk factor for the development of coagulopathy, but further conditions are required to cause PPH.
Identifiants
pubmed: 37746089
doi: 10.3389/fmed.2023.1208103
pmc: PMC10516290
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1208103Informations de copyright
Copyright © 2023 Gruneberg, Braun, Schöchl, Nachtigall-Schmitt, von der Forst, Tourelle, Dietrich, Wallwiener, Wallwiener, Weigand, Fluhr, Spratte, Hofer and Schmitt.
Déclaration de conflit d'intérêts
HS has received honoraria for participation in advisory board meetings for Alexion, Bayer Healthcare, Boehringer Ingelheim, Haemonetics and Vifor, and has received study grants and speaker's honorarium from CSL Behring. FS has received research support from CSL Behring and Philips, as well as speaker honorarium from CSL Behring and AstraZeneca and he is a consultant in an advisory board for CSL Behring. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from Enicor (consumables). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
Références
J Obstet Gynaecol Res. 2016 Nov;42(11):1509-1518
pubmed: 27785900
Br J Anaesth. 2015 Apr;114(4):623-33
pubmed: 25586727
Acta Obstet Gynecol Scand. 2022 Jan;101(1):145-152
pubmed: 34729767
J Matern Fetal Neonatal Med. 2022 Dec;35(25):9157-9162
pubmed: 35068314
AJP Rep. 2020 Jul;10(3):e241-e246
pubmed: 33133760
BMC Pregnancy Childbirth. 2020 Jul 16;20(1):409
pubmed: 32677911
Blood Coagul Fibrinolysis. 2021 Jun 1;32(4):298-301
pubmed: 33491994
Br J Anaesth. 2021 Mar;126(3):590-598
pubmed: 33422287
BMC Pregnancy Childbirth. 2018 May 9;18(1):143
pubmed: 29743045
J Matern Fetal Neonatal Med. 2022 Dec;35(25):8426-8433
pubmed: 34551661
Anesth Analg. 2020 Nov;131(5):1373-1379
pubmed: 33079858
Orv Hetil. 2020 May;161(22):899-907
pubmed: 32453702
Am J Obstet Gynecol. 2010 Apr;202(4):353.e1-6
pubmed: 20350642
N Engl J Med. 2021 Apr 29;384(17):1635-1645
pubmed: 33913640
J Matern Fetal Neonatal Med. 2022 Sep;35(18):3626-3630
pubmed: 33508987
J Thromb Thrombolysis. 2016 Oct;42(3):340-5
pubmed: 27071803
BJOG. 2021 Jan;128(1):46-53
pubmed: 32575159
A A Pract. 2023 May 05;17(5):e01676
pubmed: 37146220
Crit Care. 2023 Feb 10;27(1):55
pubmed: 36765421
Am Fam Physician. 2007 Mar 15;75(6):875-82
pubmed: 17390600
Res Pract Thromb Haemost. 2019 Nov 06;4(1):46-53
pubmed: 31989084
J Thromb Haemost. 2007 Feb;5(2):266-73
pubmed: 17087729
Transfus Med Hemother. 2021 Aug;48(4):203-209
pubmed: 34539313
Curr Opin Anaesthesiol. 2019 Jun;32(3):278-284
pubmed: 31045634
Sci Rep. 2020 Dec 9;10(1):21546
pubmed: 33298992
J Thromb Thrombolysis. 2021 May;51(4):989-996
pubmed: 32918670
BMC Pregnancy Childbirth. 2011 Nov 28;11:97
pubmed: 22123123
Thromb J. 2022 Aug 29;20(1):48
pubmed: 36038895
BMC Pregnancy Childbirth. 2009 Nov 27;9:55
pubmed: 19943928
Anaesth Crit Care Pain Med. 2016 Aug;35(4):293-8
pubmed: 27004917
Hematology Am Soc Hematol Educ Program. 2015;2015:132-7
pubmed: 26637712